Nature, last month (paywall):
The US Food and Drug Administration (FDA) will soon require [based on new federal legislation] researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants…. The diversity requirement arrives in the wake of a 2022 report from the US National Academies of Sciences, Engineering and Medicine, which found that, although the representation of white women in clinical trials has improved, progress has "largely stalled" for minority racial and ethnic groups.
